Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Spero Therapeutics to post earnings of ($0.27) per share for the quarter.

Spero Therapeutics Trading Down 0.8 %

SPRO stock opened at $1.32 on Wednesday. The stock has a market cap of $71.27 million, a PE ratio of 4.00 and a beta of 0.63. Spero Therapeutics has a 12 month low of $1.01 and a 12 month high of $1.89. The company has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.37.

Wall Street Analyst Weigh In

SPRO has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. HC Wainwright reduced their target price on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, TD Cowen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.